All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional. If you are a patient or carer, please visit the MPN Advocates Network.
The MPN Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MPN Hub cannot guarantee the accuracy of translated content. The MPN Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The MPN Hub is an independent medical education platform, sponsored by GSK, Novartis, Sumitomo, Sobi, Takeda and Karyopharm and supported through independent educational grants from Bristol Myers Squibb, Blueprint Medicines, Incyte and Merck Sharp & Dohme LLC, Rahway, NJ, USA. Funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account to access:
Bookmark & personalize site content
Receive alerts for new content in your areas of interest
View MPN content recommended for you
Results from a retrospective study evaluating clinical, morphologic, laboratory, and genetic predictors of clinical outcomes in avapritinib-treated patients from the EXPLORER (NCT02561988) and PATHFINDER (NCT03580655) trials and midostaurin-treated patients from the German Registry on Disorders and Eosinophils and Mast Cells (GREM) with advanced systemic mastocytosis (AdvSM) were published in Leukemia by Lübke et al. The key outcome assessed was overall survival (OS).
Key data: In the avapritinib group (n = 176), a risk score based on baseline mutations in SRSF2 and RUNX1 (1 point each) and SETBP1 (2 points) defined three groups with a median OS of not reached (NR) for 0 points, 45 months for 1 point, and 19 months for 2–4 points (p < 0.001). In the midostaurin group, a risk score based on baseline mutations in SRSF2 and ASXL1 (1 point each) and EZH2 (2 points) defined three groups with a median OS of 69 months for 0 points, 35 months for 1 point, and 12 months for 2–4 points (p < 0.001). In the avapritinib group, median OS was longer with an early ≥10% reduction in peripheral blood KIT D816V variant allele frequency (VAF) at Day 15 vs <10% (NR vs 47 months; p = 0.011) and with a ≥60% tryptase reduction at Month 3 vs <60% (NR vs 47 months; p < 0.001). In multivariable analyses, normalization of hemoglobin and/or platelet counts within 6 months was independently associated with longer OS with avapritinib (hazard ratio [HR], 0.275) and midostaurin (HR, 0.341), as were serum albumin normalization with avapritinib (HR, 0.177) and a ≥25% reduction in KIT D816V expressed allele burden with midostaurin (HR, 0.377).
Key learning: These findings suggest that genetic profiling and dynamic laboratory parameters may improve outcome prediction in patients with AdvSM receiving midostaurin or avapritinib, potentially informing treatment sequencing and intensification decisions; further evaluation is warranted.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
This content is accurate as of the date of publication and is not updated retrospectively. Please refer to the latest available evidence, guidelines, and relevant regulatory information when making clinical decisions.
Your opinion matters
In a patient with MPN, which finding would most increase your suspicion of coexisting systemic mastocytosis?